特发性炎性肌病的临床研究进展

doi:10.3969/j.issn.1004-583X.2022.01.016

摘要/Abstract

摘要：

特发性炎性肌病(idiopathic inflammatory myopathies,IIM)是一类罕见的临床异质性疾病,可累及多个器官或系统。IIM最初被认为仅包括皮肌炎(dermatomyositis,DM)和多肌炎(polymyositis,PM),后来随着检验、检查技术的发展及对发病机制的深入研究,IIM的分类越来越多。本文就IIM的分类、临床特点及治疗进行综述,旨在为IIM的诊断、分类及治疗提供理论依据。

中图分类号:

R685

孙瑜, 宋学琴. 特发性炎性肌病的临床研究进展[J]. 临床荟萃, 2022, 37(1): 81-86.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.01.016

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I1/81

参考文献 78

[1]	Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands[J]. Neuromuscul Disord, 2004, 14(5):337-345. doi: 10.1016/j.nmd.2004.02.006 URL
[2]	Selva-O'callaghan A, Pinal-Fernandez I, Trallero-Araguás E, et al. Classification and management of adult inflammatory myopathies[J]. Lancet Neurol, 2018, 17(9):816-828. doi: S1474-4422(18)30254-0 pmid: 30129477
[3]	Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediated necrotizing myopathies: A window on autoimmunity and cancer[J]. Front Immunol, 2017, 8:992. doi: 10.3389/fimmu.2017.00992 URL
[4]	Furst DE, Amato AA, Iorga ŞR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan[J]. Muscle Nerve, 2012, 45(5):676-683. doi: 10.1002/mus.23302 URL
[5]	薛珂, 郑捷, 曹华. 皮肌炎皮肤损害的研究进展[J]. 中国皮肤性病学杂志, 2019, 33(1):92-95.
[6]	Sontheimer RD. Dermatomyositis: An overview of recent progress with emphasis on dermatologic aspects[J]. Dermatol Clin, 2002, 20(3):387-408. pmid: 12170874
[7]	Bendewald MJ, Wetter DA, Li X, et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: A population-based study in Olmsted County, Minnesota[J]. Arch Dermatol, 2010, 146(1):26-30. doi: 10.1001/archdermatol.2009.328 pmid: 20083689
[8]	Lundberg IE, Miller FW, Tjärnlund A, et al. Diagnosis and classification of idiopathic inflammatory myopathies[J]. J Intern Med, 2016, 280(1):39-51. doi: 10.1111/joim.12524 pmid: 27320359
[9]	管宇宙. 肌电图规范化检测和临床应用共识修订版[J]. 中华神经科杂志, 2015, 48(11):950-964.
[10]	Cantwell C, Ryan M, O'connell M, et al. A comparison of inflammatory myopathies at whole-body turbo STIR MRI[J]. Clin Radiol, 2005, 60(2):261-267. pmid: 15664582
[11]	曲宁. 多发性肌炎/皮肌炎的神经肌肉活检术病理诊断[J]. 中国现代药物应用, 2011, 5(24):44-45.
[12]	Suárez-Calvet X, Gallardo E, Pinal-Fernandez I, et al. RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis[J]. Arthritis Res Ther, 2017, 19(1):174. doi: 10.1186/s13075-017-1383-0 pmid: 28738907
[13]	Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis[J]. Neurology, 2017, 88(5):493-500. doi: 10.1212/WNL.0000000000003568 URL
[14]	Betteridge Z, Mchugh N. Myositis-specific autoantibodies: An important tool to support diagnosis of myositis[J]. J Intern Med, 2016, 280(1):8-23. doi: 10.1111/joim.12451 pmid: 26602539
[15]	Petri MH, Satoh M, Martin-Marquez BT, et al. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara[J]. Arthritis Res Ther, 2013, 15(2):R48. doi: 10.1186/ar4207 URL
[16]	Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis[J]. Arthritis Rheum, 2012, 64(2):523-532. doi: 10.1002/art.v64.2 URL
[17]	Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study[J]. J Am Acad Dermatol, 2011, 65(1):25-34. doi: 10.1016/j.jaad.2010.09.016 pmid: 21531040
[18]	Labrador-Horrillo M, Martinez MA, Selva-O'callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis[J]. J Immunol Res, 2014, 2014:290797.
[19]	Sato S, Kuwana M, Fujita T, et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease[J]. Mod Rheumatol, 2013, 23(3):496-502. doi: 10.3109/s10165-012-0663-4 URL
[20]	Albayda J, Pinal-Fernandez I, Huang W, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients[J]. Arthritis Care Res (Hoboken), 2017, 69(11):1771-1776. doi: 10.1002/acr.23188 pmid: 28085235
[21]	Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts[J]. Sci Rep, 2017, 7(1):188. doi: 10.1038/s41598-017-00240-6 URL
[22]	Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients[J]. Autoimmunity, 2013, 46(4):279-284. doi: 10.3109/08916934.2012.755958 URL
[23]	Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis[J]. Ann Rheum Dis, 2009, 68(10):1621-1625. doi: 10.1136/ard.2008.097162 pmid: 18930994
[24]	Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7):344-347. doi: 10.1056/NEJM197502132920706 URL
[25]	Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts)[J]. N Engl J Med, 1975, 292(8):403-407. doi: 10.1056/NEJM197502202920807 URL
[26]	Van Der Meulen MFG, Bronner IM, Hoogendijk JE, et al. Polymyositis: An overdiagnosed entity[J]. Neurology, 2003, 61(3):316-321. pmid: 12913190
[27]	Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis[J]. Muscle Nerve, 2015, 51(5):638-656. doi: 10.1002/mus.24566 pmid: 25641317
[28]	Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis[J]. J Rheumatol, 2002, 29(9):1897-1906.
[29]	Vilela VS, Prieto-González S, Milisenda JC, et al. Polymyositis, a very uncommon isolated disease: Clinical and histological re-evaluation after long-term follow-up[J]. Rheumatol Int, 2015, 35(5):915-920. doi: 10.1007/s00296-014-3198-5 URL
[30]	Takada T, Hirakata M, Suwa A, et al. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies[J]. Mod Rheumatol, 2009, 19(2):156-164. doi: 10.3109/s10165-008-0139-8 URL
[31]	Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity[J]. Ann Rheum Dis, 2017, 76(4):681-687. doi: 10.1136/annrheumdis-2016-210198 pmid: 27651398
[32]	Wang Q, Li Y, Ji S, et al. Immunopathological characterization of muscle biopsy samples from immune-mediated necrotizing myopathy patients[J]. Med Sci Monit, 2018, 24:2189-2196. doi: 10.12659/MSM.907380 URL
[33]	Wang L, Liu L, Hao H, et al. Myopathy with anti-signal recognition particle antibodies: Clinical and histopathological features in Chinese patients[J]. Neuromuscul Disord, 2014, 24(4):335-341. doi: 10.1016/j.nmd.2014.01.002 URL
[34]	Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016[J]. Neuromuscul Disord, 2018, 28(1):87-99. doi: 10.1016/j.nmd.2017.09.016 URL
[35]	Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy[J]. J Neurol Neurosurg Psychiatry, 2016, 87(10):1038-1044. doi: 10.1136/jnnp-2016-313166 pmid: 27147697
[36]	Rönnelid J, Barbasso Helmers S, Storfors H, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies[J]. Autoimmun Rev, 2009, 9(1):58-61. doi: 10.1016/j.autrev.2009.03.005 pmid: 19285154
[37]	Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: Usefulness of myositis specific antibody[J]. Brain, 2016, 139(Pt 8):2131-2135. doi: 10.1093/brain/aww054 pmid: 27086869
[38]	Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland[J]. Neurology, 2017, 88(3):304-313. doi: 10.1212/WNL.0000000000003504 pmid: 27927941
[39]	Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia[J]. Muscle Nerve, 2000, 23(6):970-972. pmid: 10842277
[40]	Molberg Ø, Dobloug C. Epidemiology of sporadic inclusion body myositis[J]. Curr Opin Rheumatol, 2016, 28(6):657-660. doi: 10.1097/BOR.0000000000000327 pmid: 27541181
[41]	Aoki M, Suzuki N. Sporadic inclusion body myositis in Japan[J]. Nihon Rinsho, 2012, 70(5):895-906.
[42]	Li K, Pu C, Huang X, et al. Clinicopathologic features of sporadic inclusion body myositis in China[J]. Neurol Neurochir Pol, 2015, 49(4):245-250. doi: 10.1016/j.pjnns.2015.06.004 URL
[43]	Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis[J]. Neurology, 2014, 83(5):426-433. doi: 10.1212/WNL.0000000000000642 URL
[44]	de Camargo LV, de Carvalho MS, Shinjo SK, et al. Clinical, histological, and immunohistochemical findings in inclusion body myositis[J]. Biomed Res Int, 2018, 2018:5069042.
[45]	Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis[J]. Muscle nerve, 1998, 21(1):115-117. pmid: 9427231
[46]	Lee JH, Boland-Freitas R, Liang C, et al. Neuropathy in sporadic inclusion body myositis: A multi-modality neurophysiological study[J]. Clin Neurophysiol, 2020, 131(11):2766-2776. doi: 10.1016/j.clinph.2020.07.025 URL
[47]	Güttsches AK, Brady S, Krause K, et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis[J]. Ann Neurol, 2017, 81(2):227-239. doi: 10.1002/ana.24847 URL
[48]	Dalakas MC. Muscle biopsy findings in inflammatory myopathies[J]. Rheum Dis Clin North Am, 2002, 28(4):779-798. doi: 10.1016/S0889-857X(02)00030-3 URL
[49]	Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis[J]. Ann Neurol, 2013, 73(3):408-418. doi: 10.1002/ana.v73.3 URL
[50]	Muro Y, Nakanishi H, Katsuno M, et al. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts[J]. Clin Chim Acta, 2017, 472:1-4. doi: 10.1016/j.cca.2017.07.002 URL
[51]	Rietveld A, Van Den Hoogen LL, Bizzaro N, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in primary Sjögren's syndrome and systemic lupus erythematosus[J]. Front Immunol, 2018, 9:1200. doi: 10.3389/fimmu.2018.01200 pmid: 29922285
[52]	Rigolet A, Musset L, Dubourg O, et al. Inflammatory myopathies with anti-Ku antibodies: A prognosis dependent on associated lung disease[J]. Medicine (Baltimore), 2012, 91(2):95-102. doi: 10.1097/MD.0b013e31824d9cec URL
[53]	Zamora AC, Hoskote SS, Abascal-Bolado B, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome[J]. Respir Med, 2016, 118:39-45. doi: S0954-6111(16)30156-1 pmid: 27578469
[54]	Cavagna L, Nuño L, Scirè CA, et al. Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: Results from an international retrospective multicenter study[J]. Medicine (Baltimore), 2015, 94(32):e1144. doi: 10.1097/MD.0000000000001144 URL
[55]	Hervier B, Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome[J]. Curr Rheumatol Rep, 2013, 15(8):349. doi: 10.1007/s11926-013-0349-8 URL
[56]	Noguchi E, Uruha A, Suzuki S, et al. Skeletal muscle involvement in antisynthetase syndrome[J]. JAMA Neurol, 2017, 74(8):992-999. doi: 10.1001/jamaneurol.2017.0934 pmid: 28586844
[57]	Andersson H, Kirkhus E, Garen T, et al. Comparative analyses of muscle MRI and muscular function in anti-synthetase syndrome patients and matched controls: A cross-sectional study[J]. Arthritis Res Ther, 2017, 19(1):17. doi: 10.1186/s13075-017-1219-y pmid: 28122635
[58]	Witt LJ, Curran JJ, Strek ME. The Diagnosis and treatment of antisynthetase syndrome[J]. Clin Pulm Med, 2016, 23(5):218-226. doi: 10.1097/CPM.0000000000000171 URL
[59]	Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients[J]. Ann Rheum Dis, 2014, 73(1):227-232. doi: 10.1136/annrheumdis-2012-201800 pmid: 23422076
[60]	Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, et al. A longitudinal cohort study of the anti-synthetase syndrome: Increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies[J]. Rheumatology (Oxford), 2017, 56(6):999-1007. doi: 10.1093/rheumatology/kex021 pmid: 28339994
[61]	Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy[J]. Am J Med, 1993, 94(4):379-387. pmid: 8386437
[62]	Casal-Dominguez M, Pinal-Fernandez I, Huapaya J, et al. Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome[J]. Clin Exp Rheumatol, 2019, 37(5):858-861. pmid: 31074729
[63]	Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis[J]. Arch Dermatol, 2006, 142(1):65-69.
[64]	Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease[J]. J Rheumatol, 2013, 40(5):640-646. doi: 10.3899/jrheum.121043 pmid: 23457378
[65]	Labirua-Iturburu A, Selva-O'callaghan A, Martínez-Gómez X, et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease[J]. Clin Exp Rheumatol, 2013, 31(3):436-439. pmid: 23465087
[66]	Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis[J]. Rheumatology (Oxford), 2007, 46(1):124-130. doi: 10.1093/rheumatology/kel112 URL
[67]	Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis[J]. N Engl J Med, 1993, 329(27):1993-2000. doi: 10.1056/NEJM199312303292704 URL
[68]	Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis[J]. Arthritis Rheumatol, 2014, 66(3):740-749. doi: 10.1002/art.v66.3 URL
[69]	Iannone F, Scioscia C, Falappone PCF, et al. Use of etanercept in the treatment of dermatomyositis: A case series[J]. J Rheumatol, 2006, 33(9):1802-1804.
[70]	Hengstman GJD, Van Den Hoogen FHJ, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations[J]. Eur Neurol, 2003, 50(1):10-15. pmid: 12824706
[71]	Hengstman GJD, Van Den Hoogen FHJ, Van Engelen BGM. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: Long-term follow-up[J]. Eur Neurol, 2004, 52(1):61-63. pmid: 15240986
[72]	Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis[J]. Rheumatology (Oxford), 2011, 50(7):1344-1346. doi: 10.1093/rheumatology/ker152 pmid: 21515628
[73]	Zong M, Dorph C, Dastmalchi M, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: A mechanistic study with 12 months follow-up[J]. Ann Rheum Dis, 2014, 73(5):913-920. doi: 10.1136/annrheumdis-2012-202857 pmid: 23625983
[74]	Ruck T, Bittner S, Kuhlmann T, et al. Long-term efficacy of alemtuzumab in polymyositis[J]. Rheumatology (Oxford), 2015, 54(3):560-562. doi: 10.1093/rheumatology/keu484 URL
[75]	Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes[J]. Mol Ther, 2017, 25(4):870-879. doi: S1525-0016(17)30092-8 pmid: 28279643
[76]	Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis[J]. Neurology, 2006, 66(2 Suppl 1):S123-S124. doi: 10.1212/01.wnl.0000192258.32408.54 URL
[77]	Murata KY, Kouda K, Tajima F, et al. Balloon dilation in sporadic inclusion body myositis patients with dysphagia[J]. Clin Med Insights Case Rep, 2013, 6:1-7.
[78]	Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis[J]. Curr Rheumatol Rep, 2012, 14(3):244-251. doi: 10.1007/s11926-012-0248-4 pmid: 22467380

特发性炎性肌病的临床研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 78

相关文章 15

编辑推荐

Metrics

本文评价

[1]	顾天舒, 梁雪, 蔡嘉庚, 李广平. m6A RNA甲基化修饰在心血管疾病中的进展[J]. 临床荟萃, 2023, 38(8): 743-748.
[2]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[3]	吴锦秀, 苗健龙. 抗MDA5抗体阳性皮肌炎合并间质性肺病的研究进展[J]. 临床荟萃, 2022, 37(11): 1048-1052.
[4]	张媛媛, 何长健, 崔炜. 老年心力衰竭合并肌少症的研究进展[J]. 临床荟萃, 2021, 36(7): 641-645.
[5]	黄华，彭晨星，陈宇彬. 皮肌炎/多发性肌炎死亡危险因素分析[J]. 临床荟萃, 2020, 35(10): 927-930.
[6]	唐子猗a，王聃a，郑建雄a，周闻君a，秦倩a，熊琴b，易婷a，张全波b，青玉凤a. 多发性肌炎与皮肌炎合并恶性肿瘤14例临床分析[J]. 临床荟萃, 2019, 34(3): 257-261.
[7]	张宾，张二箭，田福利. 心律失常性心肌病[J]. 临床荟萃, 2017, 32(7): 561-564.
[8]	陈琪1，2，程杰2. 心房颤动与心房心肌病[J]. 临床荟萃, 2017, 32(7): 553-555.
[9]	李敬;王岚;田春辉;刘晓婷;孔繁托;张建军;刘倩;朱保月;柴瑞丽;王维展. 和肽素与缺血修饰白蛋白联合检测对急性中毒心肌损伤早期诊断的影响[J]. 临床荟萃, 2015, 30(2): 188-190195.
[10]	魏微;黄勇华;魏亚洲. 肯尼迪病2例临床分析[J]. 临床荟萃, 2014, 29(9): 1061-1063.
[11]	赵雪然;董凤群;贺新建;王立娴. 小儿过敏性紫癜的心电图改变及其临床意义[J]. 临床荟萃, 2014, 29(9): 1042-1043.
[12]	彭军;李宇林. 左卡尼汀治疗缺血性心肌病心力衰竭的临床价值[J]. 临床荟萃, 2014, 29(8): 866-868872.
[13]	汪泱;赵兰兰;陈晓梅;朱晔涵. 皮肌炎继发间质性肺疾病临床特征及预后分析[J]. 临床荟萃, 2014, 29(3): 301-304.
[14]	王正中;张兴平;何艺;李维琼;黄涛;张艳芳;王丽;冉华;蒲毅;梁伯平. 围生期心肌病血浆脑钠肽的动态变化及诊断价值[J]. 临床荟萃, 2014, 29(2): 186-188.
[15]	黄斌;吕冬华;柯孔良;宋效成;谢秋平;赵书红. 皮肌炎或多发性肌炎伴发恶性肿瘤222例国内文献复习[J]. 临床荟萃, 2013, 28(7): 792-794.